Package Leaflet: Information for theuser
Apixaban Farmalider 2.5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of theleaflet:
Apixaban Farmalider contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps prevent the formation of blood clots by blocking Factor Xa, an important element in blood coagulation.
Apixaban Farmalider is used in adults:
Do not takeApixaban Farmalider
Warnings andprecautions
Tell your doctor, pharmacist, or nurse before taking this medicine if you have any of these conditions:
This medicine will be used with caution in patients with signs of altered liver function
Be careful withApixaban Farmalider
If you know you have a disease called antiphospholipid syndrome (an immune system disorder that increases the risk of blood clots), inform your doctor to decide if it may be necessary to modify the treatment.
If you need to undergo surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a while. If you are not sure if a procedure may cause bleeding, consult your doctor.
Children andadolescents
This medicine is not recommended for use in children and adolescents under 18 years of age.
Using Apixaban Farmalider with othermedicines
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use other medicines.
Some medicines may increase the effects of apixaban, and some medicines may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of apixaban and increase the possibility of unwanted bleeding:
The following medicines may reduce the ability of apixaban to prevent blood clot formation.
Pregnancy andbreast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The effects of apixaban on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.
It is not known if apixaban is excreted in human milk. Ask your doctor or pharmacist for advice before taking this medicine during breast-feeding. They will tell you whether to stop breast-feeding or whether to stop or not start taking this medicine.
Driving and usingmachines
Apixaban has no influence on the ability to drive or use machines.
Apixaban Farmalider contains lactose (a type of sugar) andsodium.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
Follow exactly the instructions of administration of this medicine indicated by your doctor or pharmacist. If you are in doubt, consult your doctor, pharmacist, or nurse.
Dosage
Take the tablet with water. Apixaban can be taken with or without food.
Try to take the tablets at the same time each day to achieve a better effect of the treatment.
If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take apixaban. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions forcrushing:
If necessary, your doctor may also administer the crushed apixaban tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take Apixaban Farmalider according to the followingrecommendations:
To prevent the formation of blood clots in hip or knee replacement surgery.
The recommended dose of apixaban is one 2.5 mg apixaban tablet twice a day. For example, take one tablet in the morning and one in the evening.
You should take the first tablet between 12 and 24 hours after surgery.
If you have undergone major hip surgery, you will generally take the tablets for a period of 32 to 38 days.
If you have undergone major knee surgery, you will generally take the tablets for a period of 10 to 14 days.
To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor.
The recommended dose of apixaban is one 5 mg apixaban tablet twice a day.
The recommended dose is one 2.5 mg apixaban tablet twice a day if:
The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long you should continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose is two 5 mg apixaban tablets twice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose is one 5 mg apixaban tablet twice a day, for example, one tablet in the morning and one in the evening.
To prevent blood clots from recurring after 6 months of treatment
The recommended dose is one 2.5 mg apixaban tablet twice a day, for example, one tablet in the morning and one in the evening.
Your doctor will tell you how long you should continue the treatment.
Your doctor may change your anticoagulant treatment as follows:
Stop taking apixaban. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would take the next apixaban tablet.
Stop taking other anticoagulant medicines. Start treatment with apixaban at the time you would take the next dose of an anticoagulant medicine, and then continue as usual.
Stop taking the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking apixaban.
If your doctor tells you to start taking a medicine that contains a Vitamin K antagonist, continue taking apixaban for at least 2 days after your first dose of the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking apixaban.
Patients undergoingcardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor indicates to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.
If you take more Apixaban Farmalider than youshould
Tell your doctor immediatelyif you have taken a dose higher than the prescribed dose of this medicine. Take the package of the medicine to your doctor, even if there are no tablets left.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you take more apixaban than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse the anti-factor Xa activity may be necessary.
If you forget to takeApixaban Farmalider
Take the dose as soon as you remember and
If you have doubts about what to do or if you forget to take more than one dose, ask your doctor, pharmacist, or nurse.
If you stop takingApixaban Farmalider
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be higher if you stop the treatment too soon.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, apixaban can cause adverse effects, although not all people suffer from them. Apixaban can be administered for three different diseases. The known adverse effects and the frequency at which they occur may be different and are therefore indicated separately below. For these conditions, the most frequent adverse effect of this medication is bleeding, which can put the patient's life at risk and requires immediate medical attention.
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in hip or knee replacement surgeries.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Frequency Not Known (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Frequency Not Known (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to treat or prevent blood clots from recurring in the veins of the legs and in the blood vessels of the lungs.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Frequency Not Known (cannot be estimated from available data)
Skin rash that can form blisters and resemble small targets (dark spots in the center surrounded by a paler area, with a dark ring around) (erythema multiforme).
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging and on each blister, after "CAD". The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and unused medicines at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and unused medicines. This will help protect the environment.
Composition of Apixaban Farmalider
Appearance of the Product and Package Contents
The film-coated tablets are round, yellow, and have "I1" engraved on one side, with a diameter of approximately 6.1 millimeters.
Apixaban Farmalider 2.5 mg film-coated tablets are presented in blisters within cartons containing 20, 60, and 100 (clinical packaging) film-coated tablets.
Patient Information Card: Handling of Information
Inside the packaging of Apixaban Farmalider, along with the leaflet, you will find a Patient Information Card or your doctor may give you a similar card.
This Patient Information Card includes useful information for you and will alert other doctors that you are being treated with apixaban. You must keep this card with you at all times.
Marketing Authorization Holder
Farmalider S.A.
C/ La Granja, 1
28108 Alcobendas – Madrid
Spain
Manufacturers
Farmalider S.A.
C/ Aragoneses, 2
28108 Alcobendas – Madrid
Spain
Date of Last Revision of this Leaflet: April 2025
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.